• New
Licopid (glucosaminylmuramyl dipeptide) 10mg 10tablets

Licopid (glucosaminylmuramyl dipeptide) 10mg 10tablets

select a flag to translate

AfrikaansAlbanianArabicArmenianAzerbaijaniBasqueBelarusianBulgarianCatalanChinese (Simplified)Chinese (Traditional)CroatianCzechDanishDutchEnglishEstonianFilipinoFinnishFrenchGalicianGeorgianGermanGreekHaitian CreoleHebrewHindiHungarianIcelandicIndonesianIrishItalianJapaneseKoreanLatvianLithuanianMacedonianMalayMalteseNorwegianPersianPolishPortugueseRomanianSerbianSlovakSlovenianSpanishSwahiliSwedishThaiTurkishUrduVietnameseWelshYiddishBengaliBosnianKhmerLaoMaoriMongolianNepaliSomali
$34.28

 

Likopid is a drug that contains glucosaminylmuramyl dipeptide - a synthetic analogue of the structural fragment of the membrane (peptidoglycan) of bacterial cells. It is an activator of innate and acquired immunity, strengthens the body’s defense against viral, bacterial and fungal infections; has an adjuvant effect in the development of immunological reactions. Likopid is intended for the treatment and prevention of various diseases, such as recurrent infections of the upper and lower respiratory tract in the acute and remission stages, acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others), herpes infection. Take Likopid in the form of tablets orally or sublingually on an empty stomach, 30 minutes before meals, as recommended by your doctor.

The drug is used in adults and children (from 3 years of age) in the complex treatment of diseases accompanied by secondary immunodeficiency conditions:
Children
chronic, recurrent infections of the upper and lower respiratory tract in the acute stage and in remission;
- acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others);
- herpetic infection.
Adults
chronic respiratory tract infections;
- acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others); - herpetic infection.
Preventive use (adults)
- prevention and reduction of seasonal incidence of acute respiratory infections and the frequency of exacerbations of chronic diseases of the ENT organs, upper and lower respiratory tract.

Likopid® is administered orally or sublingually on an empty stomach, 30 minutes before meals.
If you miss a dose, if no more than 12 hours have passed from the scheduled time, you can take the missed dose; If more than 12 hours have passed from the scheduled time of administration, you need to take only the next dose according to the schedule and not take the missed one.
No dose adjustment is required in certain groups of patients (elderly people, patients with impaired liver function, patients with impaired renal function).
Children:
Acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others): 1 tablet 1 time per day under the tongue for 10 days.
Chronic, recurrent infections of the upper and lower respiratory tract (in the acute stage and in the remission stage): Likopid® is taken in 3 courses of 1 tablet 1 time per day under the tongue for 10 days with a break between courses of 20 days.
Herpetic infection: 1 tablet 3 times a day orally or under the tongue for 10 days.
Adults:
Chronic respiratory tract infections: 2 tablets 1 time per day under the tongue for 10 days.
Acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others): 2 tablets 2-3 times a day under the tongue for 10 days.
Herpetic infection: 2 tablets 3 times a day orally or under the tongue for 10 days.
Prevention (adults):
To prevent or reduce the seasonal incidence of acute respiratory infections and the frequency of exacerbations of diseases of the ENT organs, upper and lower respiratory tract, Likopid® is taken 1 tablet 3 times a day under the tongue for 10 days.
Precautions for use
Each Licopid® 1 mg tablet contains sucrose in the amount of 0.00042 h.u. (bread units), which should be taken into account by patients with diabetes.
Each Licopid® 1 mg tablet contains 0.074 grams of lactose, which should be taken into account by patients suffering from hypolactasia (lactose intolerance, in which the body experiences a decrease in the level of lactase, the enzyme necessary to digest lactose).

At the beginning of taking Licopid® 1 mg, an exacerbation of symptoms of chronic and latent diseases is possible, associated with the main pharmacological effects of the drug.
Effect on the ability to drive vehicles and machinery. Does not affect the ability to drive a car or operate complex machinery.

Contraindications
Hypersensitivity to glucosaminylmuramyl dipeptide and other components of the drug; pregnancy and breastfeeding;
autoimmune thyroiditis in the acute phase;
conditions accompanied by febrile temperature (>38°C) at the time of taking the drug;
rare inborn errors of metabolism: alactasia, galactosemia, lactase deficiency, lactose intolerance, sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption;
use for autoimmune diseases is not recommended due to the lack of clinical data.
Use during pregnancy and breastfeeding
Taking Licopid® 1 mg is contraindicated for women during pregnancy and breastfeeding.

4603780000022
Product added to wishlist